Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Transferase other than ribonuclease
Reexamination Certificate
1999-07-19
2001-02-20
Slobodyansky, Elizabeth (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Transferase other than ribonuclease
Reexamination Certificate
active
06190896
ABSTRACT:
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
Not Applicable
BACKGROUND
Transglutaminases are a calcium dependent family of enzymes responsible for post-translational crosslinking of proteins. The crosslinked protein products are large chemically, enzymatically, and mechanically resistant polymers with a variety of functions ranging from wound healing to skin formation (Greenberg et al., FASEB J. 5: 3071-3077 (1991)).
To date, there are several human transglutaminases which are produced from different genes. The catalytic subunit of blood-clotting factor XIIIa, or plasma transglutaminase, is 80 kDa (Ichinose et al., Proc. Natl. Acad. Sci. USA 85: 5829-5833 (1988)), the epidermal keratinocyte transglutaminase is 106 kDa (Phillips et al., Proc. Natl. Acad. Sci. 87: 933-9337 (1990)), the epidermal and hair follicle transglutaminases are 77 kDa (Kim et al., J. Biol. Chem. 268: 12682-12690 (1993)), the prostate transglutaminase is 78 kDa (Grant et al., Biochem. Biophys. Res. Comm. 203: 117-1123 (1994)), and the cellular transglutaminase is about 80 kDa (Gentile et al., J.Biol.Chem. 266: 478-483 (1991)).
Molecular cloning of cDNA for different forms of the cellular transglutaminase were reported (Gentile et al., J. Biol. Chem. 266:478-483 (1991), and a patent application number WO 92/12238), Fraij et al., J. Biol. Chem. 267: 22616-22673 (1992), and U.S. Pat. No. 5,726,051, Fraij and Gonzales, Biochim. Biophys. Acta. 1306: 63-74 (1996)). The complete organization and structure of a human cellular transglutaminase gene was recently published (Fraij and Gonzales, Biochim. Biophys. Acta. In Press (1997)).
Cellular transglutaminase is one of the most extensively studied of the transglutaminases and its crosslinking activities have been reported to be involved in skin wound healing, adhesive strength at the cartilage-cartilage interface and in the gastric mucosal injury healing (Raghunatg et al., J. Clin. Invest. 98: 1174-1184 (1996), Jurgensen et al., J. Bone and Joint Surg. 79-A: 185-193 (1997), Wang et al., Gastroenterology 104: 65-74 (1993)). Cellular transglutaminase crosslinking activities have been reported to be involved in the stabilization of apoptotic bodies (Piacentini et al., Eur. J. Cell Biol. 54: 246-254 (1991)), and to function in cellular signal transfer as a GTP receptor coupling protein (Nakaoka et al., Science 264: 1593-1596 (1994)).
Transglutaminase homologue was found recently to bind and hydrolyze GTP several fold more than the cellular transglutaminase, activities which may be related to the events of cell signaling (Fraij, Biochem. Biophys. Res. Comm. 218: 45-49 (1996)). Transglutaminase crosslinking reactions are known to occur early in regulation of receptor/membrane functions. It is evident from the patent literature that numerous concepts have been tested and are believed to have a future in the industry, however this will very much depend upon the availability and costs of the transglutaminase.
Cellular transglutaminase when compared to the other known transglutaminases, except for cellular transglutaminase, all were reported to exist as zymogen and require a limited proteolysis for full enzyme activity (Greenberg et al., FASEB J. 5: 3071-3077 (1991)). Since its discovery in 1954, the 80 kDa form of cellular transglutaminase is regarded as the active enzyme and often cited as the enzyme of the family that does not require proteolytic activation.
Transglutaminases have been used for crosslinking purposes in a variety of fields. Currently, Factor XIIIa purified from human plasma and placenta are used for intravenous injections to treat chronic venous ulcerations and as a fibrin sealant for surgery purposes. Microbial transglutaminases have found use in food industry, and since 1993 have been commercially available in Japan.
Human Factor XIIIa requires some form of activation to become catalytically active, and as each transglutaminase has certain substrates, their activities may be limited in certain applications. Therefore, what is needed in the art are methods for producing by recombinant means human transglutaminase which is catalytically active and does not require activation and does not require testing for HIV and Hepatitis viruses.
SUMMARY OF THE INVENTION
The present invention provides the ability to mass produce active cellular transglutaminase and polypeptides or fragments thereof by recombinant means in bacterial cells. Accordingly, isolated and purified polynucleotide constructs are described which code for the active transglutaminase.
In the hundreds of papers on cellular transglutaminase published since its discovery in 1954, the 80 kDa form is regarded as the active enzyme. It is often cited as the enzyme of the family that does not require proteolytic activation. However, this invention provides evidence that the 80 kDa polypeptide is an inactive precursor and can be converted in vitro and in vivo proteolytically to produce form(s) with a molecular weight of about 55 kDa, which are the active species in crosslinking reactions as summarized in this equation:
Human Cellular Transglutaminase(RBC)→Human Cellular Transglutaminase Inactive. Full length about 80 kDa Fully active, partially cleaved, about 55 kDa
In related embodiments the invention concerns DNA constructs which encode crosslinking active transglutaminase or fragment thereof, and a translational terminator, each operably linked for expression of the active enzyme. The constructs are used to transform or transfect host cells, preferably bacterial cells. The expressed active transglutaminase was purified from the bacterial cells by affinity purification.
Nucleic acid sequences of the constructs which encode the active transglutaminase of the invention and the recombinant transglutaminase itself can also be used to develop compounds which can alter transglutaminase associated apoptosis of eucaryotic cells. Antibodies raised against the active transglutaminase can be used for screening of apoptosis and for testing compounds which can act as agonists or antagonists of apoptosis-mediated mechanisms.
REFERENCES:
patent: 5549904 (1996-08-01), Juergensen et al.
patent: 5726051 (1998-03-01), Fraij
patent: WO9212238 (1992-07-01), None
Schwartz et al., “Human Factor XIII from Plasma and Platelets”,Jour of Biol. Chem.,vol. 248., No. 4, pp. 1395-1407, Feb. 1973.
Lorand et al., “A Filter Paper Assay for Transamidating Enzymes Using Radioactive Amine Substrates”,Analytical Biochemistry,50:623-631, 1972.
H.C. Birnhoim, “Rapid Extraction of High Molecular Weight RNA from Cultured cells and Granulocytes for Nothern Analysis”,Nucleic Acides Research,vol. 16, No. 4, pp. 1487-1497, 1988.
Ichinose et al., “Characterization of the Gene for the A Subunit of Human Factor XIII (Plasma Transglutaminase), a Blood Coagulation Factor”,Proc. Natl. Acad. Sci. USA.vol. 85, pp. 5829-5833, Aug. 1988.
Mary et al., “The Binding of Divalent Metal Ions to Platelet Factor XIII Modulates Its Proteolysis by Trypsin and Thrombin”,Archives of Biochemistry and Biophysics,vol. 261, No. 1, pp. 112-121, Feb. 1988.
Marchuk et al., “Construction of T-Vectors, a Rapid and General System for Direct Cloning of Unmodified PCR Products”,Nucleic Acids Research,vol. 19, No. 5, 199.
Phillips et al., “Primary Structure of Keratinocyte Transglutaminase”,Proc. Natl., Acad. Sci. USA,vol. 87, pp. 9333-9337, Dec. 1990.
Piacentini et al., “The Expression of “Tissue” Transglutaminase in Two Human Cancer Cell Lines is Related with the Programmed Cell Death (Apoptosis)”,European Journal Cell Biology,54:246-254, 1991.
Gentile et al., “Isolation and Characterization of cDNA Clones to Mouse Macrophage and Human Endothelial Cell Tissue Transglutaminases”,The Journal of Biological Chemistry,vol. 266, No. 1, pp. 478-483, Jan. 1991.
Nakanishi et al., “Cloning and Sequence Analysis of cDNA Clones for Bovine Aortic-Endothelial-Cell Transglutaminase”,Eur. J. Biochem.,202:15-21, 1991.
Greenberg et al., “Transglutaminases: Multifunctional Cross-Linking Enzymes That Stabilize Tissues”,FASEB J.,5:3071-3077, 1991.
Fraij et al., “A Retinoic Acid
Corbett Christopher W.
Slobodyansky Elizabeth
LandOfFree
Active human cellular transglutaminase does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Active human cellular transglutaminase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Active human cellular transglutaminase will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2603763